Skip to main content
. Author manuscript; available in PMC: 2017 Jul 6.
Published in final edited form as: Nature. 2016 Sep 5;539(7627):107–111. doi: 10.1038/nature19795

Extended Data Figure 8. Variable sensitivity of ccRCC lines to PT2399 and pVHL.

Extended Data Figure 8

a, Levels of the indicated mRNAs, normalized to beta actin, in UMRC-2 orthotopic tumors treated with PT2399 30 mg/kg or vehicle twice daily for 1 month; for vehicle, n=2; PT2399, n=2 mice from one experiment. b, c, Downregulation of HIF-responsive mRNAs by PT2399 in indicated cell lines. For each cell line the mRNA levels were normalized to beta actin mRNA (c) and then normalized to untreated value for that cell line (b); n=3 biological replicates. Data as median with range (a) and mean ± s.d. (b, c). d–e, Variable suppression of HIF target genes by PT2399 across a panel of ccRCC cell lines. Downregulation of HIF-responsive VEGF, Cyclin D1, and GLUT1 mRNAs by PT2399 in the indicated cell lines. For each cell line the mRNA levels were normalized to beta actin (e) and then normalized to untreated value for that cell line (d); n=3 biological replicates. SLR21 VHL+/+ renal carcinoma cell was included for comparison. Data as mean ± s.d.